Veranova began its previously announced expansion at its Devens, Massachusetts facility. 

The expansion will add 9,000 square feet to the site and include a new state-of-the-art process development laboratory and two current Good Manufacturing Practice (cGMP) suites. 

These new capabilities will expand the site’s development and production capabilities for potent compounds, ADC linker-payloads, and other complex molecules critical to next-generation therapeutics.

Veranova’s Devens site already offers a broad range of services, including cGMP laboratories, clinical and commercial kilo labs, and multi-purpose production suites. 

Mike Riley, CEO of Veranova, said, “This expansion reflects Veranova’s deep commitment to supporting our partners in the development and manufacture of complex, life-saving therapies. By enhancing our capabilities in Devens, we’re not only investing in innovation and growth, but also strengthening domestic infrastructure for the production of critical medicines like ADCs and other highly potent compounds.”

Veranova also announced a complementary investment to establish state-of-the-art bioconjugation development and cGMP manufacturing capabilities at the Devens site. 

These initiatives represent over a $50 million commitment to strengthening U.S.-based infrastructure for ADCs and bioconjugates and are expected to create up to 70 new jobs.